Indoleamine 2,3-dioxygenase expression is associated with chronic rhinosinusitis with nasal polyps and antrochoanal polyps

Rhinology

Volumn 49, Issue 3, 2011, Pages

  Honkanen, Teemu ^a,b   Luukkainen, Annika ^a   Lehtonen, Mikko ^a,b   Paavonen, Timo ^a,b   Karjalainen, Jussi ^b   Hurme, Mikko ^a,b   Myller, Jyri ^a,c   Huhtala, Heini ^d   Rau Tiainen, Markus ^a,b   Toppila Salmi, Sanna ^a,e,f  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

3 dioxyge nase; Aspirin intolerance; Chronic rhinosinusitis; Eosinophil; Indoleamine 2; Nasal polyp

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; COMORBIDITY; EOSINOPHIL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NOSE POLYP; PATHOPHYSIOLOGY; RHINITIS; SINUSITIS;

ADULT; AGED; CHRONIC DISEASE; COMORBIDITY; EOSINOPHILS; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; NASAL POLYPS; RHINITIS; SINUSITIS; YOUNG ADULT;

EID: 80051733762     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino10.191     Document Type: Article

References (36)

1. Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol. Suppl. 2007; 20: 1-136.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86: 8-160.
3. Bachert C, Van Bruaene N, Toskala E, et al. Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis - a GALEN study. Allergy. 2009; 64: 520-533.
4. Ebbens FA, Toppila-Salmi SK, Renkonen JA, et al. Endothelial L-selectin ligand expression in nasal polyps. Allergy. 2010; 65: 95-102.
5. Myller JP, Toppila-Salmi SK, Toppila EM, et al. Mucosal eosi-nophils and l-selectin ligands are associated with invasive and noninvasive sinus surgery outcomes. Am J Rhinol Allergy. 2009; 23: 21-27.
6. Jankowski R, Bouchoua F, Coffinet L, Vignaud JM. Clinical factors influencing the eosinophil infiltration of nasal polyps. Rhinology. 2002; 40: 173-178.
7. Kakoi H, Hiraide F. A histological study of formation and growth of nasal polyps. Acta Otolaryngol. 1987; 103: 137-144.
8. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006; 61: 1280-1289.
9. Van Bruaene N, Perez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008; 121: 1435-1441, 1441.e1-3.
10. Maldonado M, Martinez A, Alobid I, Mullol J. The antrochoanal polyp. Rhinology. 2004; 42: 178-182.
11. Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6037 patients. J Allergy Clin Immunol. 1977; 59: 17-21.
12. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977; 60: 276-284.
13. Kowalski ML. Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different? Thorax 2000; 55 Suppl 2:S84-S86.
14. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003; 81: 247-265.
15. Xu H, Oriss TB, Fei M, et al. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci USA. 2008; 105: 6690-6695.
16. Yoshida R, Urade Y, Tokuda M, Hayaishi O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci USA. 1979; 76: 4084-4086.
17. Daubener W, MacKenzie CR. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol. 1999; 467: 517-524.
18. von Bubnoff D, Hanau D, Wenzel J, et al. Indoleamine 2,3-diox-ygenase-expressing antigen-presenting cells and peripheral T-cell tolerance: another piece to the atopic puzzle? J Allergy Clin Immunol. 2003; 112: 854-860.
19. van der Marel AP, Samsom JN, Greuter M, et al. Blockade of IDO inhibits nasal tolerance induction. J Immunol. 2007; 179: 894-900.
20. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plas-macytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008; 181: 5396-5404.
21. Taher YA, Piavaux BJ, Gras R, et al. Indoleamine 2,3-dioxyge-nase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model. J Allergy Clin Immunol. 2008; 121: 983-991.e2.
22. Brenk M, Scheler M, Koch S, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. J Immunol. 2009; 183: 145-154.
23. Xu H, Zhang GX, Ciric B, Rostami A. IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett. 2008; 121: 1-6.
24. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med. 2007; 13: 579-586.
25. Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J.Clin.Invest. 2004; 114: 270-279.
26. Gordon JR, Li F, Nayyar A, Xiang J, Zhang X. CD8 alpha+, but not CD8 alpha-, dendritic cells tolerize Th2 responses via contact-dependent and -independent mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a mouse model of asthma. J Immunol. 2005; 175: 1516-1522.
27. Maneechotesuwan K, Wamanuttajinda V, Kasetsinsombat K, et al. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. J Allergy Clin Immunol. 2009; 123: 239-248.
28. Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice. Am J Respir Crit Care Med. 2007; 175: 561-569.
29. Wolf AM, Wolf D, Rumpold H, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol. 2004; 113: 47-55.
30. Torres MI, Lopez-Casado MA, Lorite P, Rios A. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in celiac disease. Clin Exp Immunol. 2007; 148: 419-424.
31. Sekigawa T, Tajima A, Hasegawa T, et al. Gene-expression profiles in human nasal polyp tissues and identification of genetic susceptibility in aspirin-intolerant asthma. Clin Exp Allergy 2009; 39: 972-981.
32. Scheler M, Wenzel J, Tuting T, Takikawa O, Bieber T, von Bubnoff D. Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? Am J Pathol. 2007; 171: 1936-1943.
33. Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol. 2004: 15; 173: 5909-5913.
34. Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol. 2004; 30: 311-318.
35. von Bubnoff D, Fimmers R, Bogdanow M, Matz H, Koch S, Bieber T. Asymptomatic atopy is associated with increased indoleamine 2,3-dioxygenase activity and interleukin-10 production during seasonal allergen exposure. Clin Exp Allergy 2004; 34: 1056-1063.
36. Maneechotesuwan K, Supawita S, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Sputum indoleamine-2,3-dioxy-genase activity is increased in asthmatic airways by using inhaled corticosteroids. J Allergy Clin Immunol. 2008; 121: 43-50.